A nomogram based on serum cystatin C for predicting acute kidney injury in patients with traumatic brain injury

Ruo Ran Wang**, Min He**, Xiying Gui and Yan Kang

**Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China; **Department of Critical Care Medicine, Tibet Autonomous Region People’s Hospital, Lhasa, China

ABSTRACT

Background: Acute kidney injury (AKI) is a common complication in traumatic brain injury (TBI) patients and is associated with unfavorable outcome of these patients. We designed this study to explore the value of serum cystatin C, an indicator of renal function, on predicting AKI after suffering TBI.

Methods: Patients confirmed with TBI and hospitalized in the West China Hospital of Sichuan University between January 2015 and December 2019 were included. Patients were divided into two groups according to occurrence of AKI. Univariate and multivariate logistic regression analyses were sequentially utilized to find risk factors of AKI in included TBI patients. Nomogram composed of discovered risk factors for predicting AKI was constructed. Receiver operating characteristics (ROC) curves were drawn and area under the ROC curve (AUC) were calculated to evaluate the predictive value of cystatin C alone and the constructed nomogram.

Results: Among 234 included TBI patients, 55 were divided into AKI group. AKI group had shorter length of stay (p < 0.001) and higher in-hospital mortality (p < 0.001). Multivariate logistic regression analysis showed absolute lymphocyte count (p = 0.034), serum creatinine (p < 0.001), serum cystatin C (p = 0.017) and transfusion of red blood cell (p = 0.005) were independently associated with development of AKI after TBI. While hypertonic saline use was not associated with the development of AKI (p = 0.067). The AUC of single cystatin C and predictive nomogram were 0.804 and 0.925, respectively.

Conclusion: Higher serum cystatin C is associated with development of AKI in TBI patients. Predictive nomogram incorporating cystatin C is beneficial for physicians to evaluate possibilities of AKI and consequently adjust treatment strategies to avoid occurrence of AKI.

1. Introduction

As a widely concerned public health problem, traumatic brain injury (TBI) lead to terrible mortality and disability of victims. It is estimated that approximately sixty-nine million people would suffer TBI each year all over the world [1]. The high mortality of TBI patients not only be attributable to the initial severity of brain injury, but also systemic complications secondary to brain injury [2,3]. Acute kidney injury (AKI) is one form of these systemic complications manifested as rapid occurrence of renal dysfunction. AKI after TBI has been reported developing in 7.6% to 23% patients and is correlated with mortality, functional outcome and length of hospital stay in TBI patients [4–7]. Mechanisms involved in development of AKI after TBI are diversified, which included systemic inflammation response, neuroendocrine hormone release, hypoperfusion and iatrogenic factors such as blood transfusion, drugs reducing intracranial pressure and usage of nephrotoxic antibiotics [8–11]. In view of the unfavorable outcome caused by AKI, exploring novel and available biomarkers to predict the possible occurrence of AKI in early stage and consequently avoid medical treatments adverse to normal renal function is beneficial for outcome and recovery of TBI patients.

The cystatin C, a kind of endogenous cysteine proteinase inhibitor taking part in the catabolism of intracellular proteins and peptides, has been demonstrated as an effective marker of renal function [12,13]. Compared with creatinine, life cycle of serum cystatin C is shorter which makes it capable of detecting declined renal function earlier than serum creatinine and more

CONTACT Yan Kang kangyan@scu.edu.cn
Department of Critical Care Medicine, West China Hospital, No. 37, Guo Xue Xiang, Chengdu, China

These authors contributed equally to this work.

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
applicable in emergency condition [13–15]. In addition, cystatin C is less likely to be influenced by muscle wasting, malnutrition, age and sex than creatinine, which indicates it may be more reliable and accurate in reflecting glomerular filtration rate (GFR) [12,16–18]. Predictive value of serum cystatin C on evaluating occurrence of AKI has been confirmed in various groups of patients including critically ill patients, patients undergoing cardiac surgery and those receiving radiocontrast medium [19–25]. However, there are no studies exploring the association between serum cystatin C level and occurrence of AKI after TBI. Therefore, we designed this study to testify the hypothesis that serum cystatin C is an effective marker of AKI in TBI patients.

2. Materials and methods

2.1. Patients

This observational study was retrospectively conducted in West China hospital of Sichuan University. We included TBI patients treated in neuro-intensive care unit (NICU) of West China hospital between January 2015 and December 2019. TBI patients hospitalized in our NICU were mostly confirmed with moderate to severe TBI patients (GCS <13) who required continuous intensive care and organ function support. Diagnoses of included patients were confirmed by analyzing radiological signs in computed tomography (CT) scans. Patients were excluded from this study if they met following criteria: (1) admitted to West China hospital 4 h after suffering injury; (2) hospitalized in West China hospital less than 48 h; (3) history of severe underlying diseases such as severe cardiovascular diseases, stroke, malignant hypertension, severe metabolic diseases, severe hepatorenal diseases and active cancer; (4) incomplete clinical data included in this study; (5) history of surgical operation within 4 weeks before TBI. Finally, 234 patients were included in this single center retrospective study. Our study was approved by the ethics committee of West China hospital (2018-359) and conducted accorded with Declaration of Helsinki. Informed consent form about clinical study of each patients was routinely signed by patients themselves or their legally authorized representatives during their hospitalization.

2.2. Data collection

All clinical and laboratory variables included in this study were collected from records of electronic medical record (EMR) system in West China hospital. Demographic variables such as age and gender, injury mechanisms, vital signs on admission including systolic blood pressure, diastolic blood pressure, heart rate, body temperature and respiratory rate were collected in this study. Occurrence of anisocoria and Glasgow Coma Scale (GCS) on admission were also recorded. Variables of blood routine and blood biochemistry examination including serum cystatin C level were obtained by analyzing blood samples collected at admission. Serum concentrations of cystatin C was detected using the Cobas 8000 chemistry autoanalyzer (Roche Diagnostics, Switzerland). Anatomic injury types including epidural hematoma, subdural hematoma, intracerebral hematoma, subarachnoid hemorrhage, intraventricular hemorrhage and diffused axonal injury were recorded according to findings of CT scans. Red blood cell (RBC) transfusion, usage of drugs for reducing intracranial pressure and types of surgical operation were included. Outcome of this study was the occurrence of AKI in TBI patients during their hospitalization. AKI was diagnosed based on the KIDGO criteria from the second day after admission to discharge.

2.3. Statistical analysis

We used Kolmogorov-Smirnov test to testify the normality of included variables. Normally distributed variables and non-normally distributed variables were presented in the form of mean ± standard deviation and median (interquartile range), respectively. Categorical variables were shown as counts (percentage). Student’s t-test was utilized to compare the difference between two groups of normally distributed variables. And Mann-Whitney U test was performed to analyzed the difference between two groups of non-normally distributed variables. Chi-square test or Fisher exact test were conducted to confirm the difference between two groups of categorical variables. Univariate and multivariate logistic regression analysis were sequentially performed to explore independent risk factor for AKI after TBI. Odds ratio (OR) and 95% confidence intervals (CI) of each risk factors were calculated and presented. Discovered independent risk factors were combined to construct logistic regression model for predicting AKI after TBI. For convenient clinical use, the predictive model was visualized using nomogram. Receiver operating characteristic (ROC) curves of single and constructed predictive model were drawn and area under the ROC curve (AUC) value of them were calculated. Z test was conducted to verify the difference of AUC between single serum cystatin C and the predictive model.
Two-tailed P value <0.05 was considered to be statistically significant. SPSS 22.0 (IBM Corp., Armonk, NY, USA) and R (version 3.6.1; R Foundation) was used to carry out all statistical analyses and figures drawing.

3. Results

3.1. Comparison of baseline characteristics between non-AKI and AKI patients

A total of 234 patients confirmed with TBI were included in this study. Patients were divided into two groups based on whether they developed AKI during hospitalization. As a result, 179 patients were included in non-AKI group and 55 patients were selected into AKI group with AKI incidence of 23.5% (Table 1). The average age of overall patients was 44 and the male ratio of overall was 77.8%. Among recorded injury mechanisms, motor vehicle collision was the leading cause of initial brain injury. High falling and stumbling injury ranked the second and third, respectively. Compared with non-AKI group, AKI groups showed no significant difference on admission vital signs including systolic blood pressure, diastolic blood pressure, heart rate, body temperature and respiratory rate. Occurrence rate of anisocoria also did not significantly differ between non-AKI group and AKI group (35.8% vs 36.4%, p = 0.934). While AKI group had significantly lower GCS score than non-AKI group (5 vs 6, p < 0.001).

Results of routine laboratory tests presented that AKI group had lower platelet count (89 vs 125, p < 0.001), hemoglobin (90 vs 92, p = 0.001), fibrinogen (2.22 vs 3.07, p = 0.044), albumin (29.2 vs 31.8, p = 0.004) and cholesterol (2.02 vs 2.82, p < 0.001) than non-AKI group.

Table 1. Baseline characteristics of non-AKI group and AKI group in included TBI patients.

| Variables                      | Overall patients (N = 234) | Non-AKI group (n = 179) | AKI group (n = 55) | p Value |
|--------------------------------|-----------------------------|-------------------------|-------------------|---------|
| Age (years)                    | 44 (28–59)                  | 43 (27–56)              | 47 (34–64)        | 0.092   |
| Sex (male ratio)               | 182 (77.8%)                 | 136 (76%)               | 46 (83.6%)        | 0.220   |
| Injury mechanism               |                             |                         |                   |         |
| Traffic accident               | 148 (63.2%)                 | 112 (62.6%)             | 36 (65.5%)        | 0.697   |
| High falling                   | 40 (20.9%)                  | 37 (20.7%)              | 12 (21.8%)        | 0.855   |
| Stumble                        | 22 (9.4%)                   | 15 (8.4%)               | 7 (12.7%)         | 0.349   |
| Others                         | 15 (6.4%)                   | 15 (8.4%)               | 0                 | 0.025   |
| Vital signs on admission       |                             |                         |                   |         |
| Systolic blood pressure (mmHg) | 123 (108–141)               | 125 (110–141)           | 120 (103–146)     | 0.326   |
| Diastolic blood pressure (mmHg)| 73.79 ± 16.58               | 74.07 ± 15.32           | 72.87 ± 20.29     | 0.687   |
| Heart rate (min⁻¹)             | 98 (81–120)                 | 96 (80–116)             | 107 (86–121)      | 0.066   |
| Body temperature (°C)          | 36.8 (35.6–37.1)            | 36.8 (36.5–37.1)        | 36.8 (36.5–37.8)  | 0.610   |
| Respiratory rate (min⁻¹)       | 20 (17–23)                  | 20 (17–23)              | 20 (16–22)        | 0.615   |
| Anisocoria                     | 84 (35.9%)                  | 64 (35.8%)              | 20 (36.4%)        | 0.934   |
| GCS                            | 6 (4–8)                     | 6 (5–9)                 | 5 (3–6)           | <0.001  |
| Laboratory tests               |                             |                         |                   |         |
| White blood cell (10⁹/L)       | 15.09 (11.14–20.43)         | 14.84 (11.27–19.49)     | 15.76 (10.58–23)  | 0.362   |
| Neutrophil (10⁹/L)             | 11.61 (8.64–15.77)          | 11.38 (8.77–15.60)      | 12.32 (7.67–17.54) | 0.927   |
| Lymphocyte (10⁹/L)             | 0.82 (0.54–1.16)            | 0.84 (0.55–1.22)        | 0.75 (0.46–1.02)  | 0.071   |
| Platelet (10⁹/L)               | 115 (78–169)                | 125 (86–179)            | 89 (54–136)       | <0.001  |
| Hemoglobin (g/L)               | 90 (77–106)                 | 92 (79–110)             | 80 (72–91)        | 0.001   |
| Fibrinogen (mg/L)              | 2.86 (1.68–4.27)            | 3.07 (1.78–4.45)        | 2.22 (1.23–4.06)  | 0.044   |
| Albumin (g/L)                  | 31.2 ± 5.9                  | 31.8 ± 6.0              | 29.2 ± 5.4        | 0.004   |
| Cholesterol (mmol/L)           | 2.66 (1.95–3.51)            | 2.82 (2.21–3.67)        | 2.02 (1.44–2.76)  | <0.001  |
| Lactate dehydrogenase (U/L)    | 380 (291–533)               | 363 (270–491)           | 474 (344–726)     | <0.001  |
| Blood urea nitrogen (mmol/L)   | 6.11 (4.70–8.67)            | 5.77 (4.43–7.77)        | 9.34 (5.8–14.61)  | <0.001  |
| Serum creatinine (umol/L)      | 71 (56–98)                  | 65 (51–81)              | 124 (98–172)      | <0.001  |
| Serum cystatin C (mg/L)        | 0.78 (0.63–0.97)            | 0.72 (0.60–0.89)        | 1.09 (0.85–1.65)  | <0.001  |
| Radiological findings          |                             |                         |                   |         |
| Epidural hematoma              | 30 (12.8%)                  | 29 (16.2%)              | 1 (1.8%)          | 0.001   |
| Subdural hematoma              | 93 (39.7%)                  | 71 (39.7%)              | 22 (40%)          | 0.965   |
| Intracerebral hematoma         | 81 (34.6%)                  | 61 (34.1%)              | 20 (36.4%)        | 0.756   |
| Subarachnoid hemorrhage        | 102 (43.6%)                 | 80 (44.7%)              | 22 (40%)          | 0.538   |
| Intraventricular hemorrhage    | 15 (6.4%)                   | 12 (6.7%)               | 3 (5.5%)          | 1.000   |
| Diffused axonal injury         | 35 (15%)                    | 29 (16.2%)              | 6 (10.9%)         | 0.321   |
| Treatment options              |                             |                         |                   |         |
| Transfusion of RBC             | 86 (36.8%)                  | 57 (31.8%)              | 29 (52.7%)        | 0.006   |
| Mannitol                       | 174 (74.4%)                 | 136 (76.0%)             | 38 (69.1%)        | 0.313   |
| Fructose glycerol              | 25 (10.7%)                  | 20 (11.2%)              | 5 (9.1%)          | 0.657   |
| Hypertonic saline              | 84 (35.9%)                  | 74 (41.3%)              | 10 (18.2%)        | 0.001   |
| Decompressive craniectomy      | 86 (36.8%)                  | 63 (35.2%)              | 23 (41.8%)        | 0.376   |
| Hematoma evacuation            | 98 (41.9%)                  | 75 (41.9%)              | 23 (41.8%)        | 0.991   |
| Length of ICU stay (days)      | 13 (2–25)                   | 14 (4–25)               | 5 (2–27)          | 0.057   |
| Length of hospital stay (days) | 22 (8–39)                   | 24 (11–41)              | 9 (3–29)          | <0.001  |
| In-hospital mortality          | 95 (40.6%)                  | 54 (30.2%)              | 41 (74.5%)        | <0.001  |

GCS: Glasgow Coma Scale; RBC: red blood cell.
Table 2. Univariate and multivariate logistic regression analysis of risk factors for AKI after TBI.

| Variables                        | Univariate logistic regression analysis | Multivariate logistic regression analysis |
|----------------------------------|----------------------------------------|------------------------------------------|
|                                  | OR          | 95% Cl       | p     | OR          | 95% Cl       | p  |
| Age (years)                      | 1.015       | 0.999–1.032  | 0.065 |             |              |    |
| Sex (male)                       | 1.616       | 0.732–3.569  | 0.235 |             |              |    |
| Systolic blood pressure (mmHg)  | 0.997       | 0.985–1.009  | 0.597 |             |              |    |
| Diastolic blood pressure (mmHg) | 0.996       | 0.978–1.014  | 0.638 |             |              |    |
| Heart rate (min⁻¹)               | 1.009       | 0.998–1.021  | 0.104 |             |              |    |
| Body temperature (°C)            | 1.108       | 0.804–1.528  | 0.530 |             |              |    |
| Respiratory rate (min⁻¹)         | 1.004       | 0.950–1.061  | 0.894 |             |              |    |
| Anisocoria                       | 1.027       | 0.548–1.925  | 0.934 |             |              |    |
| GCS                              | 0.735       | 0.633–0.854  | <0.001|             |              |    |
| White blood cell (10⁹/L)         | 1.030       | 0.987–1.075  | 0.177 |             |              |    |
| Neutrophil (10⁹/L)               | 0.997       | 0.977–1.019  | 0.815 |             |              |    |
| Lymphocyte (10⁹/L)               | 0.520       | 0.277–0.976  | 0.042 | 0.324       | 0.114–0.920  | 0.034|
| Platelet (10⁹/L)                 | 0.993       | 0.988–0.998  | 0.004 |             |              |    |
| Hemoglobin (g/L)                 | 0.981       | 0.966–0.996  | 0.012 |             |              |    |
| Fibrinogen (mg/L)                | 0.877       | 0.743–1.035  | 0.120 |             |              |    |
| Albumin (g/L)                    | 0.926       | 0.877–0.977  | 0.005 |             |              |    |
| Cholesterol (mmol/L)             | 0.479       | 0.336–0.684  | <0.001|             |              |    |
| Lactate dehydrogenase (U/L)      | 1.002       | 1.001–1.003  | 0.001 |             |              |    |
| Blood urea nitrogen (mmol/L)     | 1.334       | 1.199–1.485  | <0.001|             |              |    |
| Serum creatinine (mmol/L)        | 1.061       | 1.042–1.079  | <0.001|             |              |    |
| Serum cystatin C (mg/L)          | 51.742      | 13.176–203.187| <0.001|             |              |    |
| Epidural hematoma                | 0.096       | 0.013–0.720  | 0.023 |             |              |    |
| Subdural hematoma                | 1.014       | 0.547–1.879  | 0.965 |             |              |    |
| Intracerebral hematoma           | 1.105       | 0.589–2.076  | 0.755 |             |              |    |
| Subarachnoid hemorrhage          | 0.825       | 0.446–1.525  | 0.540 |             |              |    |
| Intraventricular hemorrhage      | 0.803       | 0.218–2.955  | 0.741 |             |              |    |
| Diffused axonal injury           | 0.633       | 0.248–1.615  | 0.339 |             |              |    |
| Transfusion of RBC               | 2.387       | 1.290–4.419  | 0.006 | 4.212       | 1.541–11.515 | 0.005|
| Mannitol                         | 0.707       | 0.363–1.377  | 0.308 |             |              |    |
| Fructose glycerol                | 0.795       | 0.284–2.227  | 0.663 |             |              |    |
| Hypertonic saline                | 0.315       | 0.149–0.666  | 0.002 | 0.357       | 0.119–1.074  | 0.067|
| Decompressive craniectomy         | 1.323       | 0.714–2.454  | 0.374 |             |              |    |
| Hematoma evacuation              | 0.997       | 0.540–1.839  | 0.991 |             |              |    |

OR: odds ratio; CI: confidence interval; GCS: Glasgow Coma Scale; RBC: red blood cell.

With statistical significance. However, the level of lactate dehydrogenase (LDH) (474 vs 363, p < 0.001), blood urea nitrogen (BUN) (9.34 vs 5.77, p < 0.001), serum creatinine (SCr) (124 vs 65, p < 0.001) and serum cystatin C (1.09 vs 0.72, p < 0.001) were obviously higher in AKI group than non-AKI group. Radiological findings showed that non-AKI group was more frequently observed with epidural hematoma (16.2% vs 1.8%, p = 0.001). Other types of brain injury did not significantly differ between these two groups. Records of treatments indicated that patients with AKI were more likely to receive red blood cell (RBC) transfusion (52.7% vs 31.8%, p = 0.006) and less likely to be treated with hypertonic saline (18.2% vs 41.3%, p = 0.376). Compared with non-AKI group, AKI group had shorter length of hospital stay (9 vs 24, p < 0.001) and higher mortality rate (74.5% vs 30.2%, p < 0.001).

3.2. Univariate and multivariate logistic regression analysis of risk factors for AKI

We primarily performed univariate logistic regression and found that GCS (OR = 0.735, p < 0.001), absolute lymphocyte count (OR = 0.520, p = 0.042), platelet (OR = 0.999, p = 0.004), hemoglobin (OR = 0.981, p = 0.012), albumin (OR = 0.926, p = 0.005), cholesterol (OR = 0.479, p < 0.001) and epidural hematoma (OR = 0.906, p = 0.023) were negatively correlated with occurrence of AKI in included TBI patients (Table 2). While LDH (OR = 1.002, p = 0.001), BUN (OR = 1.334, p < 0.001), SCr (OR = 1.061, p < 0.001) and serum cystatin C (OR = 51.742, p < 0.001) were positively related with development of AKI in included TBI patients. Subsequently, we included significant factors above mentioned in univariate analysis into multivariate logistic regression. After adjusting confounding effects, only lymphocyte count (OR = 0.324, p = 0.034), SCr (OR = 1.052, p < 0.001) and epidural hematoma (OR = 0.324, p < 0.001) were significantly associated with development of AKI during hospitalization.

3.3. Value of serum cystatin C and constructed logistic model for predicting AKI in TBI patients

The AUC of ROC curves (Figure 1) about predicting AKI was listed in Table 3. The AUC of serum cystatin C alone was 0.804, which was lower than 0.925 of logistic
predictive model comprised of lymphocyte count, Scr, cystatin C and RBC transfusion. For convenient clinical use, we drawn readily visualized nomogram of this predictive model (Figure 2(A)). The calibration curve of this model showed good consistency between actual probabilities and predicted probabilities of AKI (Figure 2(B)).

4. Discussion

This is the first study to confirm the value of serum cystatin C on predicting AKI in TBI patients. In this study, we found that lymphocyte count, Scr, cystatin C and RBC transfusion were independently associated with development of AKI in TBI patients. The single cystatin C level was effective in predicting AKI while combining four factors above mentioned was more accurate than cystatin C alone in evaluating the possible occurrence of AKI in TBI patients.

The development of AKI is a prevalent non-neurologic complication in TBI patients, which has been reported occurring in 7.6% to 23% TBI patients [4–7]. Multiple mechanisms may be involved in the development of AKI after TBI including massive catecholamine release, various inflammatory mediators induced systemic inflammation [3,26]. The catecholamine surge, mainly characterized as a massive release of norepinephrine, epinephrine, and dopamine is a necessary pathophysiologic process after TBI and could stimulate the activation of renin-angiotensin-aldosterone-system (RAAS) which subsequently aggravates the deteriorating renal function [3,27,28]. In addition, many kinds of inflammatory mediators including IL-1β, IL-6 and CRP would be released from injured brain tissue to circulation. These inflammatory mediators could accelerate the progression of systemic organ damage. Previous studies have showed that CRP and IL-6 level was associated with the development of systemic inflammatory response syndrome (SIRS) [29,30]. Furthermore, some studies have confirmed the value of CRP, IL-6 and SIRS on predicting AKI in several clinical settings [31–33]. In brain death organ donors, inflammatory responses mediated by Mitogen-activated protein kinases (MAP-kinases) were considered playing an important role in kidney injury [34]. Therefore, the association between AKI and TBI may similarly be mediated by the activation of systemic inflammation.

Previous studies have illustrated the prognostic role of serum cystatin C in a variety of critically ill patients [35–41]. Non-survivors commonly had higher initial or

|               | AUC     | 95% CI  | Sensitivity | Specificity |
|---------------|---------|---------|-------------|-------------|
| Cystatin C    | 0.804   | 0.727–0.880 | 0.655       | 0.894       |
| Predictive model | 0.925   | 0.883–0.967 | 0.764       | 0.961       |

AUC: area under the ROC curve; CI: confidence interval.
mean serum cystatin C level than survivors. For patients with neurological diseases, it has been confirmed that level of cystatin C was positively related with severity and adverse outcome of acute ischemic stroke, aneurysmal subarachnoid hemorrhage [42–46]. One study found that concentration of cystatin C in cerebrospinal fluid would increase in TBI patients [47]. Increase of serum cystatin C was also observed in patients suffering acute spinal cord injury [48]. Actually, increased production of cystatin C was an auto neural-protective response to protease hyperactivation in brain tissue and was beneficial for blood-brain barrier integrity and

Figure 2. (A) Nomogram of the constructed logistic model for predicting AKI in included TBI patients. The nomogram consisted of four variables including lymphocyte, serum creatinine, serum cystatin C and records of RBC transfusion. Based on the sum of corresponding points of each variable, total points could be calculated and therefore evaluated the risk of AKI. (B) Calibration plot for predicting AKI in included TBI patients.
attenuation of early brain injury [47,49–51]. Therefore, we could infer that increased serum cystatin C was partially attributable to brain injury severity and the real value of cystatin C on reflecting renal function may be confounded by the injury severity. However, after adjusting the confounding effects of GCS, an indicator of brain injury severity, in multivariate logistic regression analysis, we found that higher cystatin C was independently associated with occurrence of AKI which indicated that increased cystatin C was an effective and accurate marker of declined renal function in TBI patients.

The mechanism of cystatin C as biomarker of renal function is that it is freely filtered through the glomerulus and completely reabsorbed and catabolized by proximal renal tubular cells. Decreased renal GFR could lead to the accumulation of cystatin C in circulation. Therefore, increased serum cystatin C level could be rationally considered as an indicator of AKI characterized as rapid deterioration of urinary function. Serum creatinine or creatinine clearance was previously acknowledged as an indicator of GFR. However, association between serum creatinine and urinary function of kidney was usually influenced by hemodilution, muscle mass, nutrition, age and sex [12,18,52]. Whereas the fact that serum cystatin C level was less likely to be affected by these factors made it more reliable and effective in detecting early minimal reduction of GFR. In addition, previous studies discovered that life cycle of serum cystatin C was half of that of SCr and increase of cystatin C level above 50% preceded SCr increase by 1.5 days to detect acute renal failure [13,14,53]. Consequently, cystatin C may be a more precise and prompter marker of GFR which could shorten the diagnosis delay in acute clinical settings. Compared with other newly discovered marker of AKI such as TIMP2-IGFBP7 (combination of tissue inhibitor of metalloproteinas 2 and insulin-like growth factor binding protein 7) or NGAL, cystatin C is more readily available. Because physicians could easily obtain the serum cystatin C level from the result of inexpensive blood biochemistry test. In our study, multivariate logistic regression analysis showed that SCr and serum cystatin C both were independent risk factors of AKI in TBI patients. Besides, lymphocyte count was also incorporated in our constructed predictive model. It has been confirmed that various lymphocytes including T cells and B cells both play significant role in initiation, progression and recovery of AKI [54–56]. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were discovered correlated with AKI in many clinical settings [57–60]. RBC transfusion was also confirmed as a latent risk factor for developing AKI in some kinds of patients especially those undergoing cardiac surgery [61–64]. Therefore, incorporating lymphocyte count and RBC transfusion into the predictive nomogram may increase the accuracy and stability. Finally, although use of hypertonic saline was associated with reduced risk of developing AKI in univariate analysis, it was not still statistically significant in multivariate analysis. The correlation between hypertonic saline use and AKI has been studied in many researches without definite conclusions. Some researchers indicated that hypertonic saline could raise serum chloride and sodium concentrations which could cause renal vasoconstriction and consequently decrease renal perfusion [65,66]. However, the correlation between use of hypertonic saline, hyperchloremia and AKI in brain injured patients has not been widely acknowledged [67,68]. One study found prolonged duration of hyperchloremia rather than the duration of hypertonic saline infusion or the highest chloride value was associated with AKI in TBI patients [69]. Another study indicated that neurologically injured patients received infusion of hypertonic saline with a high chloride load were more likely to develop hyperchloremia and AKI [67]. Because no detailed dosage of hypertonic saline was recorded in our study, a further study exploring the relationship between duration of hypertonic saline, serum chloride level and development of AKI is worth to conduct.

There were several limitations in this study. Firstly, this was a single center observational study with relatively small sample size. Further study with larger sample size should be conducted in other medical centers to confirm the predictive value of cystatin C and the constructed nomogram. Secondly, although some confounding factors have been included in this study, some risk factors influencing renal function such as usage of nephrotoxic antibiotics and serum osmolality were not recorded in this study. In addition, history of underlying diseases including hypertension, coronary heart disease and chronic kidney disease were not included into statistical analysis due to the small portion of these diseases. Thirdly, detailed dosage of drugs reducing intracranial pressure including mannitol, fructose glycerol and hypertonic saline was not collected in this study so that we could not accurately evaluate influences of these drugs on renal function. Finally, included TBI patients in this study were mainly diagnosed with moderate to severe TBI and received treatments in NICU. Conclusions of our study should be verified in more generalized TBI patients.
5. Conclusions

Serum cystatin C level is independently associated with the development of AKI in TBI patients. Predictive nomogram incorporating cystatin C is effective in evaluating possible occurrence of AKI in TBI patients.

Ethical approval

This study was approved by the ethics committee of West China hospital and conducted accorded with Declaration of Helsinki. Informed consent form about clinical study of each patients was routinely signed by patients themselves or their legally authorized representatives during their hospitalization.

Author contributions

RW was involved in the data collection, data analysis, and drafting of the manuscript. MH was involved in interpretation of the results. YK interpreted the results and contributed to the reviewing of the draft.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The study was financially supported by the 1·3·5 project for disciplines of excellence—Clinical Research Incubation Project, West China Hospital, Sichuan University [19HXFH012].

ORCID

Yan Kang http://orcid.org/0000-0002-5715-3900

References

[1] Dewan MC, Rattani A, Gupta S, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018;130(4):1080–1097.
[2] Zygun DA, Kortbeek JB, Fick GH, et al. Non-neurologic organ dysfunction in severe traumatic brain injury. Crit Care Med. 2005;33(3):654–660.
[3] Zygun D. Non-neurological organ dysfunction in neurocritical care: impact on outcome and etiological considerations. Curr Opin Crit Care. 2005;11(2):139–143.
[4] Moore EM, Bellomo R, Nichol A, et al. The incidence of acute kidney injury in patients with traumatic brain injury. Renal Failure. 2010;32(9):1060–1065.
[5] Li N, Zhao WG, Zhang WF. Acute kidney injury in patients with severe traumatic brain injury: implementation of the acute kidney injury network stage system. Neurocrit Care. 2011;14(3):377–381.
[6] Skrifvars MB, Moore E, Martensson J, et al; The EPO-TBI Investigators and the ANZICS Clinical Trials Group. Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial. Acta Anaesthesiol Scand. 2019;63(2):200–207.
[7] Corral L, Javieire CF, Ventura JL, et al. Impact of non-neurological complications in severe traumatic brain injury outcome. Crit Care. 2012;16(2):R44.
[8] Sadan O, Singbartl K, Kraft J, et al. Low-chloride versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage-related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial. J Intensive Care. 2020;8(1):32.
[9] Büttner S, Stadler A, Mayer C, et al. Incidence, risk factors, and outcome of acute kidney injury in neurocritical care. J Intensive Care Med. 2020;35(4):338–346.
[10] An S, Luo H, Wang J, et al. An acute kidney injury prediction nomogram based on neurosurgical intensive care unit profiles. Ann Transl Med. 2020;8(5):194–194.
[11] Deng Y, Yuan J, Chi R, et al. The incidence, risk factors and outcomes of postoperative acute kidney injury in neurosurgical critically Ill patients. Sci Rep. 2017;7(1):4245.
[12] Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–226.
[13] Odutayo A, Cherney D. Cystatin C and acute changes in glomerular filtration rate. Clin Nephrol. 2012;78(1):64–75.
[14] Sjöström P, Tidman M, Jones I. The shorter T1/2 of cystatin C explains the earlier change of its serum level compared to serum creatinine. Clin Nephrol. 2004;62(3):241–242.
[15] Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2008;23(12):2151–2157.
[16] Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29–34.
[17] Nejat M, Pickering JW, Walker RJ, et al. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dialysis Transplantation. 2010;25(10):3283–3289.
[18] Swaminathan M, Phillips-Bute BG, Conlon PJ, et al. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg. 2003;76(3):784–791.
[19] Deng Y, Chi R, Chen S, et al. Evaluation of clinically available renal biomarkers in critically ill adults: a prospective multicenter observational study. Crit Care. 2017;21(1):46.
[20] Rickli H, Benou K, Ammann P, et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiotransfer media. Clin Nephrol. 2004;61(2):98–102.
[21] Delanaye P, Lambermont B, Chapelle JP, et al. Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Medicine. 2004;30(5):980–983.

[22] El-Sadek AE, El-Gamasy MA, Behiry EG, et al. Plasma cystatin C versus renal resistive index as early predictors of acute kidney injury in critically ill neonates. J Pediatr Urol. 2020;16(2):206.e1–e201-206.e208.

[23] Wang X, Lin X, Xie B, et al. Early serum cystatin C-enhanced risk prediction for acute kidney injury post cardiac surgery: a prospective, observational, cohort study. Biomarkers. 2020;25(1):20–26.

[24] Krawczeski CD, Vandevoorde RG, Kathman T, et al. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. CJASN. 2010;5(9):1552–1557.

[25] Zappitelli M, Greenberg JH, Coca SG, et al.; Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) Consortium. Association of definition of acute kidney injury by cystatin C rise with biomarkers and clinical outcomes in children undergoing cardiac surgery. JAMA Pediatr. 2015;169(6):583–591.

[26] Lim HB, Smith M. Systemic complications after head injury: a clinical review. Anaesthesia. 2007;62(5):474–482.

[27] Dudoignon E, Moreno N, Deniau B, et al. Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19. Anaesth Crit Care Pain Med. 2020;39(4):243–455.

[28] Chen YT, Chan CK, Li WY, et al. Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients. J Formosan Med Assoc Taiwan yi Zhi. 2021;120(1):641–650.

[29] Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, et al. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma. 2008;65(3):646–652.

[30] Staubli SM, Schäfer J, Rosenthal R, et al. The role of CRP and Pentraxin 3 in the prediction of systemic inflammatory response syndrome and death in acute pancreatitis. Sci Rep. 2019;9(1):18340.

[31] Zhang WR, Garg AX, Coca SG, TRIBE-AKI Consortium, et al. Plasma IL-6 and IL-10 concentrations predict AKI and long-term mortality in adults after cardiac surgery. J Am Soc Nephrol. 2015;26(12):3123–3132.

[32] Maiwall R, Chandel SS, Wani Z, et al. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis. Dig Dis Sci. 2016;61(3):920–929.

[33] Yang BH, He Q, Ding CY, et al. High-sensitivity C-reactive protein as a predictive factor of acute kidney injury following aneurysmal subarachnoid hemorrhage: a prospective observational study. Acta Neurochir (Wien). 2019;161(9):1783–1791.

[34] Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant. 2009;9(5):989–997.

[35] Seo YS, Park SY, Kim MY, et al. Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. J Gastroenterol Hepatol. 2018;33(4):910–917.

[36] Hendrickson CM, Kwong YD, Belzer AG, et al. Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy. Crit Care. 2020;24(1):416.

[37] Bell M, Granath F, Mårtensson J, et al.; KING (Karolinska Intensive care Nephrology Group). Cystatin C is correlated with mortality in patients with and without acute kidney injury. Nephrol Dial Transplant. 2009;24(10):3096–3102.

[38] Angeli F, Verdecchia P, Savonitto S, et al. Cystatin C and risk of mortality among patients undergoing percutaneous coronary intervention. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the. Eur Soc Cardiol. 2015;11(8):757–764.

[39] Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45(2):268–271.

[40] Volpon LC, Sugo EK, Carlotti AP. Diagnostic and prognostic value of serum cystatin C in critically ill children with acute kidney injury. Pediatric Crit Care Med. 2015;16(5):e125–131.

[41] Luo J, Wang LP, Hu HF, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis. Clin Chim Acta Inter J Clin Chem. 2015;450:39–45.

[42] Shi J, Zhang C, Cao Y, et al. Prognostic value of cystatin C in acute ischemic stroke patients with intravenous thrombolysis. CNR. 2019;16(4):301–309.

[43] Zhang JB, Jü XH, Wang J, et al. Serum cystatin C and cerebral microbleeds in patients with acute cerebral stroke. J Clin Neurosci. 2014;21(2):268–273.

[44] Zhu Z, Zhong C, Xu T, et al. Prognostic significance of serum cystatin C in acute ischemic stroke patients according to lipid component levels. Atherosclerosis. 2018;274:146–151.

[45] Goksu E, Goksu E, Karsli B, et al. Cerebrospinal fluid cystatin C levels following treatment for aneurysmal subarachnoid hemorrhage. Turk Neurosurg. 2014;24(3):391–397.

[46] Zeng Q, Lin K, Yao M, et al. Significant correlation between cystatin C, cerebral infarction, and potential biomarker for increased risk of stroke. CNR. 2015;12(1):40–46.

[47] Hanrieder J, Wetterhall M, Enblad P, et al. Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates. J Neurosci Methods. 2009;177(2):469–478.

[48] Zhang J, Ding R, Xian Q, et al. Serum cystatin C is increased in acute spinal cord injury: a multicentre retrospective study. Spinal Cord. 2020;58(3):341–347.

[49] Liu Y, Li J, Wang Z, et al. Attenuation of early brain injury and learning deficits following experimental subarachnoid hemorrhage secondary to Cystatin C: possible involvement of the autophagy pathway. Mol Neurobiol. 2014;49(2):1043–1054.

[50] Liu Y, Cai H, Wang Z, et al. Induction of autophagy by cystatin C: a potential mechanism for prevention of
cerebral vasospasm after experimental subarachnoid hemorrhage. Eur J Med Res. 2013;18(1):21.

[51] Yang B, Xu J, Chang L, et al. Cystatin C improves blood-brain barrier integrity after ischemic brain injury in mice. J Neurochem. 2020;153(3):413–425.

[52] Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597–1605.

[53] Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115–1122.

[54] Weller S, Varrier M, Ostermann M. Lymphocyte function in human acute kidney injury. Nephron. 2017;137(4):287–293.

[55] Inaba A, Tuong ZK, Riding AM, et al. B lymphocyte-derived CCL7 augments neutrophil and monocyte recruitment, exacerbating acute kidney injury. J Immunol. 2020;205(5):1376–1384.

[56] Zheng L, Gao W, Hu C, et al. Immune cells in ischemic acute kidney injury. Curr Protein Pept Sci. 2019;20(8):770–776.

[57] Zheng CF, Liu WY, Zeng FF, et al. Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury. Crit Care. 2017;21(1):238.

[58] Gameiro J, Lopes JA. Complete blood count in acute kidney injury prediction: a narrative review. Ann Intensive Care. 2019;9(1):87.

[59] Bu X, Zhang L, Chen P, et al. Relation of neutrophil-to-lymphocyte ratio to acute kidney injury in patients with sepsis and septic shock: A retrospective study. Int Immunopharmacol. 2019;70:372–377.

[60] Bi JB, Zhang J, Ren YF, et al. Neutrophil-to-lymphocyte ratio predicts acute kidney injury occurrence after gastrointestinal and hepatobiliary surgery. World J Gastrointest Surg. 2020;12(7):326–333.

[61] Karkouti K, Grocott HP, Hall R, et al. Interrelationship of preoperative anemia, intraoperative anemia, and red blood cell transfusion as potentially modifiable risk factors for acute kidney injury in cardiac surgery: a historical multicentre cohort study. Can J Anesth. 2015;62(4):377–384.

[62] Karkouti K, Wijeyasurya DN, Yau TM, et al. Influence of erythrocyte transfusion on the risk of acute kidney injury after cardiac surgery differs in anemic and non-anemic patients. Anesthesiology. 2011;115(3):523–530.

[63] Maaranen P, Huusko A, Tauriainen T, et al. Blood transfusion and outcome after transfemoral transcatheter aortic valve replacement. J Cardiothoracic Vasc Anesthesia. 2019;33(11):2949–2959.

[64] Nilsson CU, Bentzer P, Andersson LE, et al. Mortality and morbidity of low-grade red blood cell transfusions in septic patients: a propensity score-matched observational study of a liberal transfusion strategy. Ann Intensive Care. 2020;10(1):111.

[65] Chowdhury AH, Cox EF, Francis ST, et al. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-Lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012;256(1):18–24.

[66] Kumar AB, Shi Y, Shotwell MS, et al. Hypernatremia is a significant risk factor for acute kidney injury after subarachnoid hemorrhage: a retrospective analysis. Neurocrit Care. 2015;22(2):184–191.

[67] Sigmon J, May CC, Bryant A, et al. Assessment of acute kidney injury in neurologically injured patients receiving hypertonic sodium chloride: does chloride load matter? Ann Pharmacother. 2020;54(6):541–546.

[68] Jiang S, Shen Y, Zhao X. Hyperchloremia is associated with acute kidney injury in patients with aneurysmal subarachnoid hemorrhage: not sure. Crit Care Med. 2017;45(10):e1099.

[69] Yamane DP, Maghami S, Graham A, et al. Association of hyperchloremia and acute kidney injury in patients with traumatic brain injury. J Intens Care Med. 2020:885066620978735.